Population Health Research Institute
Study List

CREATE/OASIS-3 (Completed)
The Clinical Trial of REviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation

< back

 


The trial evaluated effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. The trial found that in patients with acute ST-segment elevation  reviparin reduces mortality and reinfarction, without a substantive increase in overall stroke rates. There was  a small absolute excess of life-threatening bleeding but the benefits outweigh the risks.

Study Design: Randomized controlled trial with partial 2x2 factrial design.

Intervention: Reviparin vs. placebo.

Length of Study: 3 years

# of Patients: 15,570 

Patient Populations: ST-segment elevation acute myocardial infarction.


Presentations

CREATE - Reviparin & GIK - Final Results


Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, Zhu J, Liu L; CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293(4): 427-35.

 

 

 

 

 

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca